Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.

Authors

null

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY

Sandra P. D'Angelo, Matthias Hunger, Michael Schlichting, Meliessa G. Hennessy, Murtuza Bharmal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02155647

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 193)

DOI

10.1200/JCO.2018.36.5_suppl.193

Abstract #

193

Poster Bd #

K2

Abstract Disclosures